Deferred Tax Assets, Net of Valuation Allowance of CRISPR Therapeutics AG from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
CRISPR Therapeutics AG quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • CRISPR Therapeutics AG Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2025 was $65,093,000, a 11% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $65,093,000 -$7,652,000 -11% 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q4 2024 $72,745,000 -$7,423,000 -9.3% 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q4 2023 $80,168,000 -$2,807,000 -3.4% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q4 2022 $82,975,000 +$8,798,000 +12% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q4 2021 $74,177,000 +$53,985,000 +267% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q4 2020 $20,192,000 +$5,152,000 +34% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q4 2019 $15,040,000 +$11,206,000 +292% 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q4 2018 $3,834,000 -$29,000 -0.75% 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q4 2017 $3,863,000 -$2,277,000 -37% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q4 2016 $6,140,000 +$5,661,000 +1182% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q4 2015 $479,000 31 Dec 2015 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.